Infectious Disease
Sort
At a recent virtual town hall, leaders of the Pacific Northwest RECOVER hub shared what they’ve learned so far about long COVID — from symptom trajectories and genetic risk to early trial results and upcoming studies — and answered questions from participants about risk factors, persistent symptoms and what comes next.
Researchers from the NIH-funded RECOVER study shared new insights on the risks of Long COVID, autoimmune links, and upcoming clinical trials during ISB’s July Town Hall.
In a Research Roundtable presentation and Q&A, ISB President Dr. Jim Heath shared how his team is using generative AI to unlock new understanding of human immunity, and how these discoveries could help predict disease severity, improve cancer therapies, and more.
Scientists at the Institute for Systems Biology (ISB) reveal how T cells “decide” their fate in fighting infections like COVID-19, paving the way for improved treatments for infections, cancer, and autoimmune diseases.
ISB hosted a virtual event to share updates on the ongoing RECOVER study, a national NIH-funded initiative to understand and address Long COVID.
By using a computer model to understand the adaptions of Mycobacterium tuberculosis (Mtb), the pathogen that causes tuberculosis, researchers at ISB have identified a network within Mtb that allows it to tolerate and resist drug therapies. This work is published in Cell Reports.